BACKGROUND: Patients with glioblastoma multiforme (GBM) exhibit marked intratumoral and systemic immunosuppression. GBM is heavily infiltrated with monocytic cells. Monocytes contacting GBM cells develop features of immunosuppressive myeloid-derived suppressor cells (MDSCs), which are elevated in GBM patients. Therefore, we hypothesized that circulating MDSC levels could be raised in vivo by increasing glioma-associated macrophages. METHODS: GL261-luciferase glioma was implanted intracranially in C57BL/6 mice with or without additional normal syngeneic CD11b+ monocytes. Tumor growth and intratumoral and systemic MDSC (CD11b+/Gr-1+) levels were determined. Green fluorescent protein (GFP)-transgenic monocytes were coinjected intracranially with GL261-luciferase cells. GFP+ cell frequency among splenic and bone marrow MDSCs was determined. Impact of increased MDSC's on spontaneous immune responses to tumor cells expressing a model antigen (ovalbumin [OVA]) was determined. RESULTS: Tumors grew faster and MDSC's were increased in tumor, spleen, and bone marrow in mice receiving GL261-Luc plus monocytes. Many (30%-50%) systemic MDSC's were GFP+ in mice receiving intracranial tumor plus GFP-transgenic monocytes, suggesting that they originated from glioma-associated monocytes. Tumor-infiltrating OVA-specific CD8+ T cells were markedly reduced in mice receiving GL261-OVA and monocytes compared with mice receiving GL261-OVA alone. CONCLUSIONS: Increasing glioma-associated macrophages in intracranial GL261 glioma decreases survival and markedly increases intratumoral and systemic MDSC's, many of which originate directly from glioma-associated macrophages. This is associated with decreased spontaneous immune responses to a model antigen. To our knowledge, this is the first evidence in cancer that systemic MDSC's can arise directly from normal monocytes that have undergone intratumoral immunosuppressive education.
BACKGROUND:Patients with glioblastoma multiforme (GBM) exhibit marked intratumoral and systemic immunosuppression. GBM is heavily infiltrated with monocytic cells. Monocytes contacting GBM cells develop features of immunosuppressive myeloid-derived suppressor cells (MDSCs), which are elevated in GBM patients. Therefore, we hypothesized that circulating MDSC levels could be raised in vivo by increasing glioma-associated macrophages. METHODS:GL261-luciferase glioma was implanted intracranially in C57BL/6 mice with or without additional normal syngeneic CD11b+ monocytes. Tumor growth and intratumoral and systemic MDSC (CD11b+/Gr-1+) levels were determined. Green fluorescent protein (GFP)-transgenic monocytes were coinjected intracranially with GL261-luciferase cells. GFP+ cell frequency among splenic and bone marrow MDSCs was determined. Impact of increased MDSC's on spontaneous immune responses to tumor cells expressing a model antigen (ovalbumin [OVA]) was determined. RESULTS:Tumors grew faster and MDSC's were increased in tumor, spleen, and bone marrow in mice receiving GL261-Luc plus monocytes. Many (30%-50%) systemic MDSC's were GFP+ in mice receiving intracranial tumor plus GFP-transgenic monocytes, suggesting that they originated from glioma-associated monocytes. Tumor-infiltrating OVA-specific CD8+ T cells were markedly reduced in mice receiving GL261-OVA and monocytes compared with mice receiving GL261-OVA alone. CONCLUSIONS: Increasing glioma-associated macrophages in intracranial GL261glioma decreases survival and markedly increases intratumoral and systemic MDSC's, many of which originate directly from glioma-associated macrophages. This is associated with decreased spontaneous immune responses to a model antigen. To our knowledge, this is the first evidence in cancer that systemic MDSC's can arise directly from normal monocytes that have undergone intratumoral immunosuppressive education.
Authors: Michael P Gustafson; Yi Lin; Kent C New; Peggy A Bulur; Brian Patrick O'Neill; Dennis A Gastineau; Allan B Dietz Journal: Neuro Oncol Date: 2010-02-23 Impact factor: 12.300
Authors: Kelli P A MacDonald; Vanessa Rowe; Andrew D Clouston; Joseph K Welply; Rachel D Kuns; James L M Ferrara; Ranjeny Thomas; Geoffrey R Hill Journal: J Immunol Date: 2005-02-15 Impact factor: 5.422
Authors: Linda M Liau; Robert M Prins; Sylvia M Kiertscher; Sylvia K Odesa; Thomas J Kremen; Adrian J Giovannone; Jia-Wei Lin; Dennis J Chute; Paul S Mischel; Timothy F Cloughesy; Michael D Roth Journal: Clin Cancer Res Date: 2005-08-01 Impact factor: 12.531
Authors: Mitsugu Fujita; Xinmei Zhu; Ryo Ueda; Kotaro Sasaki; Gary Kohanbash; Edward R Kastenhuber; Heather A McDonald; Gregory A Gibson; Simon C Watkins; Ravikumar Muthuswamy; Pawel Kalinski; Hideho Okada Journal: Cancer Res Date: 2009-02-03 Impact factor: 12.701
Authors: Joseph A Flores-Toro; Defang Luo; Adithya Gopinath; Matthew R Sarkisian; James J Campbell; Israel F Charo; Rajinder Singh; Thomas J Schall; Meenal Datta; Rakesh K Jain; Duane A Mitchell; Jeffrey K Harrison Journal: Proc Natl Acad Sci U S A Date: 2019-12-26 Impact factor: 11.205
Authors: Dimitrios Mathios; Chul-Kee Park; Warren D Marcus; Sarah Alter; Peter R Rhode; Emily K Jeng; Hing C Wong; Drew M Pardoll; Michael Lim Journal: Int J Cancer Date: 2015-07-28 Impact factor: 7.396
Authors: Jean-Pierre Gagner; Yasmeen Sarfraz; Valerio Ortenzi; Fawaz M Alotaibi; Luis A Chiriboga; Awab T Tayyib; Garry J Douglas; Eric Chevalier; Barbara Romagnoli; Gérald Tuffin; Michel Schmitt; Guillaume Lemercier; Klaus Dembowsky; David Zagzag Journal: Am J Pathol Date: 2017-07-20 Impact factor: 4.307
Authors: Yuping D Li; Jonathan B Lamano; Jason B Lamano; Jessica Quaggin-Smith; Dorina Veliceasa; Gurvinder Kaur; Dauren Biyashev; Dusten Unruh; Orin Bloch Journal: Cancer Immunol Immunother Date: 2019-09-05 Impact factor: 6.968
Authors: Gregory J Baker; Peter Chockley; Daniel Zamler; Maria G Castro; Pedro R Lowenstein Journal: Oncoimmunology Date: 2016-03-16 Impact factor: 8.110
Authors: Susan Brandenburg; Kati Turkowski; Annett Mueller; Yordan T Radev; Sabine Seidlitz; Peter Vajkoczy Journal: Immunol Res Date: 2017-06 Impact factor: 2.829